Hogerzeil et.al. published this week a report, on the behalf of the Lancet NCD Action group. They described very elegantly, the different challenges facing NCD prevention. They shared take home messages from the infectious diseases world and discussed the drugs cost/patent issues.
Hope you will find this report useful and hope you can also share your reflections about it.